Eli Lilly and Company (LLY) to Release Quarterly Earnings on Thursday

Eli Lilly and Company (NYSE:LLY - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Eli Lilly and Company to post earnings of $5.56 per share and revenue of $14.40 billion for the quarter.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. During the same quarter in the prior year, the firm earned $2.58 EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. On average, analysts expect Eli Lilly and Company to post $23 EPS for the current fiscal year and $31 EPS for the next fiscal year.

Eli Lilly and Company Trading Up 2.9%

NYSE LLY traded up $21.40 on Friday, hitting $761.47. The company's stock had a trading volume of 4,857,388 shares, compared to its average volume of 3,808,815. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company's 50-day simple moving average is $774.56 and its 200 day simple moving average is $799.73. The firm has a market cap of $721.68 billion, a P/E ratio of 61.96, a PEG ratio of 1.08 and a beta of 0.40.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. UBS Group cut their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Guggenheim raised their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,012.56.

Institutional Investors Weigh In On Eli Lilly and Company

An institutional investor recently raised its position in Eli Lilly and Company stock. Revolve Wealth Partners LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,471 shares of the company's stock after acquiring an additional 40 shares during the quarter. Revolve Wealth Partners LLC's holdings in Eli Lilly and Company were worth $1,136,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.